Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice

Atherosclerosis

Volumn 149, Issue 1, 2000, Pages 199-205

  Barter, P J ^a   O'Brien, R C ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Atorvastatin; General practice; Hypercholesterolaemia; Simvastatin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; SIMVASTATIN;

ADULT; AGED; ARTICLE; AUSTRALIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENERAL PRACTICE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTYRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0033995230     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00402-5     Document Type: Article

References (15)

1. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 1994;344:1383-89.
2. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Eng. J. Med. 333:1995;1301-1307.
3. Sacks F.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Eng. J. Med. 335:1996;1001-1009.
4. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
5. Gould A.L., Rossouw J.E., Santanello N.C. et al. Cholesterol reduction yields clinical benefit impact of statin trials. Circulation. 97:1998;946-952.
6. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 308:1994;367-373.
7. Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial, JAMA 1990;263:1795-1801.
8. Hoerger T.J., Bala M.V., Bray J.W. et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible US adults. Am. J. Cardiol. 82:1998;61-65.
9. Allain C.C., Poon L.C., Chan C.S.G. et al. Enzymatic determination of total serum cholesterol. Clin. Chem. 20:1974;470-475.
10. Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem. 19:1973;476-482.
11. Burstein M., Scholnick H.R., Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid Res. 11:1970;583-595.
12. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the ultracentrifuge. Clin. Chem. 18:1972;499-502.
13. Jones P., Kafonek S., Laurora I. et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am. J. Cardiol. 81:1998;582-587.
14. Dart A., Jerums G., Nicholson G. et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardiol. 80:1997;39-44.
15. Simons L.A. Comparison of atorvastatin alone versus simvastatin+cholestyramine in the management of severe primary hypercholesterolaemia (The Six Cities Study). Aust. NZ J. Med. 28:1998;327-333.